Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology.

The award is another strong external validation and recognition of the AI-Immunology platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History Museum in London. Evaxion and AI-Immunology was chosen by a committee of distinguished scientific leaders among 10 candidates.

“We are honored to receive this distinction, which rewards the unique capabilities of AI-Immunology in effective vaccine target discovery, design and development. We are even more proud since this is the second recognition from the Galien Prix Foundation in less than a year. This kind of external validation is a great boost to our efforts to continuously improve AI-Immunology and bring forward safe and effective vaccine candidates in cancer and infectious disease,” says Helen Tayton-Martin.

In its evaluation, the jury focused on the innovation demonstrated throughout each candidate’s scientific development, clinical application, and utility. Further consideration was given to the insights it has advanced in biomedical science and the product's tangible impact on human health.

This is not the first time Evaxion has been recognized by the Galien Prix Foundation. In December 2025, we received the award for the Best Medical Technology / AI Advances in the Nordic and high-growth European and Middle Eastern countries.

The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK's leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.

Schreibe Deinen Kommentar